Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.35 |
| ▸ | CNR2 | P34972 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175911 | 0.93 | CNR2 (0.41) | CNR2CNR1MEN1NPC1KMT2A | |
| SCHEMBL18197337 | 0.93 | PNLIP (0.36) | MAOBCNR2CNR1 | |
| SCHEMBL20175917 | 0.93 | CNR2 (0.41) | CNR2CNR1MEN1NPC1KMT2A | |
| SCHEMBL20175919 | 0.92 | MAPT (0.42) | CNR2CNR1MEN1NPC1KMT2A | |
| SCHEMBL18197180 | 0.91 | MAPT (0.37) | MAOBCNR2MEN1NPC1KMT2A | |
| SCHEMBL18197339 | 0.91 | PDE3B (0.41) | CNR2CNR1 | |
| SCHEMBL12841233 | 0.91 | OPRK1 (0.36) | KDM4E | |
| SCHEMBL15029754 | 0.91 | OPRK1 (0.36) | KDM4E | |
| SCHEMBL18189632 | 0.91 | KDM4E (0.36) | MAOBMEN1NPC1KMT2AKDM4E | |
| SCHEMBL18189634 | 0.91 | KDM4E (0.36) | MAOBMEN1NPC1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2016176343-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570104-B2 | Metabolically programmed metal chelators and uses thereof | FECH, SLC19A1, SLC40A1 | MAOB 658/4885CNR2 3585/4885CNR1 3794/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | MAOB 658/4885CNR2 3585/4885CNR1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.